Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

599 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use and perceived utility of [18 F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022.
Ambrosini V, Caplin M, Castaño JP, Christ E, Denecke T, Deroose CM, Dromain C, Falconi M, Grozinsky-Glasberg S, Hicks RJ, Hofland J, Kjaer A, Knigge UP, Kos-Kudla B, Koumarianou A, Krishna B, Lamarca A, Pavel M, Reed NS, Scarpa A, Srirajaskanthan R, Sundin A, Toumpanakis C, Prasad V. Ambrosini V, et al. Among authors: hicks rj. J Neuroendocrinol. 2024 Jan;36(1):e13359. doi: 10.1111/jne.13359. Epub 2023 Dec 14. J Neuroendocrinol. 2024. PMID: 38097193
ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors.
Borbath I, Pape UF, Deprez PH, Bartsch DK, Caplin M, Falconi M, Garcia-Carbonero R, Grozinsky-Glasberg S, Jensen RT, Arnold R, Ruszniewski P, Toumpanakis C, Valle JW, O Toole D; Members of the Advisory Board of the European Neuroendocrine Tumor Society (ENETS). Borbath I, et al. J Neuroendocrinol. 2022 Mar;34(3):e13105. doi: 10.1111/jne.13105. Epub 2022 Mar 1. J Neuroendocrinol. 2022. PMID: 35233848 Review.
Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy.
Li M, Chan DL, Tapia Rico G, Cehic G, Lawrence B, Wyld D, Pattison DA, Kong G, Hicks R, Michael M, Kiberu AD, Lim J, Clifton-Bligh R, Tsang V, Roach PJ, Leyden J, Diakos CI, Price TJ, Pavlakis N. Li M, et al. Neuroendocrinology. 2023;113(3):281-288. doi: 10.1159/000526848. Epub 2022 Sep 1. Neuroendocrinology. 2023. PMID: 36049462 Free article. Review.
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.
Wild D, Grønbæk H, Navalkissoor S, Haug A, Nicolas GP, Pais B, Ansquer C, Beauregard JM, McEwan A, Lassmann M, Pennestri D, Volteau M, Lenzo NP, Hicks RJ. Wild D, et al. Among authors: hicks rj. Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):183-195. doi: 10.1007/s00259-023-06383-1. Epub 2023 Sep 18. Eur J Nucl Med Mol Imaging. 2023. PMID: 37721581 Free PMC article. Clinical Trial.
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours.
Schürrle SB, Eberlein U, Ansquer C, Beauregard JM, Durand-Gasselin L, Grønbæk H, Haug A, Hicks RJ, Lenzo NP, Navalkissoor S, Nicolas GP, Pais B, Volteau M, Wild D, McEwan A, Lassmann M. Schürrle SB, et al. Among authors: hicks rj. Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2428-2441. doi: 10.1007/s00259-024-06682-1. Epub 2024 Mar 26. Eur J Nucl Med Mol Imaging. 2024. PMID: 38528164 Free PMC article. Clinical Trial.
Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert Consensus statement.
Taïeb D, Nölting S, Perrier ND, Fassnacht M, Carrasquillo JA, Grossman AB, Clifton-Bligh R, Wanna GB, Schwam ZG, Amar L, Bourdeau I, Casey RT, Crona J, Deal CL, Del Rivero J, Duh QY, Eisenhofer G, Fojo T, Ghayee HK, Gimenez-Roqueplo AP, Gill AJ, Hicks R, Imperiale A, Jha A, Kerstens MN, de Krijger RR, Lacroix A, Lazurova I, Lin FI, Lussey-Lepoutre C, Maher ER, Mete O, Naruse M, Nilubol N, Robledo M, Sebag F, Shah NS, Tanabe A, Thompson GB, Timmers HJLM, Widimsky J, Young WJ Jr, Meuter L, Lenders JWM, Pacak K. Taïeb D, et al. Nat Rev Endocrinol. 2024 Mar;20(3):168-184. doi: 10.1038/s41574-023-00926-0. Epub 2023 Dec 14. Nat Rev Endocrinol. 2024. PMID: 38097671 Review.
High Detection Rates for Prostate-specific Membrane Antigen-avid Prostate Cancer Recurrence at Low Prostate-specific Antigen levels on Extended Axial Field-of-view Positron Emission Tomography/Computed Tomography.
Thomas S, Callahan J, Conway P, Moon D, Morgan H, Ingbritsen J, Munro M, Ware RE, Dundee P, Hicks RJ. Thomas S, et al. Among authors: hicks rj. Eur Urol Open Sci. 2024 Dec 7;71:49-56. doi: 10.1016/j.euros.2024.11.008. eCollection 2025 Jan. Eur Urol Open Sci. 2024. PMID: 39720335 Free PMC article.
A cutting-edge technology for the future of nuclear medicine.
Glaudemans AWJM, Lammertsma AA, Cherry SR, Erba PA, Rominger A, Dierckx RAJO, Boellaard R, Hammers A, Hicks RJ, Slart RHJA. Glaudemans AWJM, et al. Among authors: hicks rj. Eur J Nucl Med Mol Imaging. 2024 Dec 11. doi: 10.1007/s00259-024-07028-7. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 39661126 No abstract available.
Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force.
Prasad V, Koumarianou A, Denecke T, Sundin A, Deroose CM, Pavel M, Christ E, Lamarca A, Caplin M, Castaño JP, Dromain C, Falconi M, Grozinsky-Glasberg S, Hofland J, Knigge UP, Kos-Kudla B, Krishna BA, Reed NS, Scarpa A, Srirajaskanthan R, Toumpanakis C, Kjaer A, Hicks RJ, Ambrosini V. Prasad V, et al. Among authors: hicks rj. J Neuroendocrinol. 2024 Dec 9:e13479. doi: 10.1111/jne.13479. Online ahead of print. J Neuroendocrinol. 2024. PMID: 39653582
599 results